A Phase 1/2 Study of Ponatinib in Japanese Patients With Chronic Myeloid Leukemia (CML) and Ph+ Acute Lymphoblastic Leukemia (ALL)
by on Friday, August 17th, 2012 | No Comments
Conditions: Chronic Myeloid Leukemia (CML); Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)
Interventions: Drug: ponatinib - Phase 1; Drug: ponatinib - Phase 2
Sponsors: Ariad Pharmaceuticals; Ariad Pharmaceuticals
Recruiting – verified August 2012
Read the original: A Phase 1/2 Study of Ponatinib in Japanese Patients With Chronic Myeloid Leukemia (CML) and Ph+ Acute Lymphoblastic Leukemia (ALL)